Altheos Lands $12,500,000 Series A Financing Round

  • Feed Type
  • Date
  • Company Name
  • Mailing Address
    601 Gateway Blvd. South San Francisco, CA 94080
  • Company Description
    Altheos, Inc. is focused on the development of a best-in-class next-generation eye drop treatment for glaucoma. The lead compound, ATA907, is a selective rho-kinase (ROCK) inhibitor developed specifically for topical treatment of glaucoma which Altheos licensed from a Japanese pharmaceutical company.
  • Website
  • Transaction Type
    Venture Equity
  • Transaction Amount
  • Transaction Round
    Series A
  • Proceeds Purposes
    The increase of our Series A round allows us the opportunity to advance our lead candidate to phase 3 trials.
  • M&A Terms
  • Venture Investor
    Bay City Capital
  • Venture Investor
    Novo A/S
  • Venture Investor
    Canaan Partners
  • Venture Investor

Trending on Xconomy